Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 6/2020

Open Access 01-06-2020 | Oral Cancer | Original Article

Extent of neck dissection for patients with clinical N1 oral cancer

Authors: Yasumasa Kakei, Hirokazu Komatsu, Tsutomu Minamikawa, Takumi Hasegawa, Masanori Teshima, Hirotaka Shinomiya, Naoki Otsuki, Ken-ichi Nibu, Masaya Akashi

Published in: International Journal of Clinical Oncology | Issue 6/2020

Login to get access

Abstract

Background

No clear consensus has been reached on the indication of supraomohyoid neck dissection (SOHND) for clinically positive lymph-node metastasis.

Patients

Consecutive 100 patients with previously untreated oral cancer treated at Kobe University Hospital were included in this study. All patients were clinically staged as anyTN1M0 and underwent radical dissection of the primary site and level I–V neck dissection as the initial treatment.

Results

None of the 100 patients had pathological lymph-node metastasis (pLN) to level V. pLN to level IV was observed in two patients with tongue cancer in whom clinical lymph-node metastasis was preoperatively observed at level II.

Conclusions

Level V may be excluded in the neck dissection for patients with N1 oral cancers. Level IV dissection should be considered in the patient with tongue cancer and clinical lymph-node metastasis at level II.
Literature
1.
Ferlito A, Som PM, Rinaldo A et al (2000) Classification and terminology of neck dissections. ORL J Otorhinolaryngol Relat Spec 62:212–216CrossRefPubMed
2.
Shah JP, Candela FC, Poddar AK (1990) The patterns of cervical lymph node metastases from squamous carcinoma of the oral cavity. Cancer 66:109–113CrossRefPubMed
3.
Brazilian Head and Neck Cancer Study Group (1998) Results of a prospective trial on elective modified radical classical versus supraomohyoid neck dissection in the management of oral squamous carcinoma. Am J Surg 176:422–427CrossRef
4.
Fasunla AJ, Greene BH, Timmesfeld N et al (2011) A meta-analysis of the randomized controlled trials on elective neck dissection versus therapeutic neck dissection in oral cavity cancers with clinically node negative neck. Oral Oncol 47:320–324CrossRefPubMed
5.
D'Cruz AK, Vanish R, Kapre N et al (2015) Elective versus therapeutic neck dissection in node-negative oral cancer. N Engl J Med 373:521–529CrossRefPubMed
6.
Schilling C, Shaw R, Schache A et al (2017) Sentinel lymph node biopsy for oral squamous cell carcinoma. Where are we now? Br J Oral Maxillofac Surg 55:757–762CrossRefPubMed
7.
Kowalski LP, Carvalho AL (2002) Feasibility of supraomohyoid neck dissection in N1 and N2a oral cancer patients. Head Neck 128:1180–1184
8.
Asakage T, Kishimoto S, Saikawa M et al (2005) The standardization of neck dissection for tongue carcinoma. Toukeibu Gan 31(4):536–540 (in Japanese) CrossRef
9.
Sun R, Tang X, Yang Y et al (2015) (18)FDG-PET/CT for the detection of regional nodal metastasis in patients with head and neck cancer: a meta-analysis. Oral Oncol 51(4):314–320CrossRefPubMed
10.
Liao LJ, Lo WC, Hsu WL et al (2012) Detection of cervical lymph node metastasis in head and neck cancer patients with clinically N0 neck-a meta-analysis comparing different imaging modalities. BMC Cancer 12:236CrossRefPubMedPubMedCentral
11.
Andersen PE, Warren F, Spiro J et al (2002) Results of selective neck dissection in management of the node-positive neck. Arch Otolaryngol Head Neck Surg 128(10):1180–1184CrossRefPubMed
12.
Suzuki M, Yoshino K, Fujii T et al (2009) Appropriate area of neck dissection for N1 tongue cancer. Toukeibu Gan 35(4):370–373 (in Japanese) CrossRef
13.
Harada H, Omura K, Shimamoto H (2014) Selective neck dissection for oral squamous cell carcinoma. Toukeibu Gan 40(1):16–22 (in Japanese) CrossRef
14.
Shimbashi W, Kawabata K, Mitani H et al (2012) Appropriate area of selective neck dissection for tongue carcinoma. Toukeibu Gan 38(4):425–429 (in Japanese) CrossRef
15.
Dias FL, Lima RA, Kligerman J et al (2006) Relevance of skip metastases for squamous cell carcinoma of the oral tongue and the floor of the mouth. Otolaryngol Head Neck Surg 134(3):460–465CrossRefPubMed
16.
Koerdt S, Röckl J, Rommel N et al (2016) Lymph node management in the treatment of oral cancer: analysis of a standardized approach. J Craniomaxillofac Surg 44(10):1737–1742CrossRefPubMed
17.
Liang L, Zhang T, Kong Q et al (2015) A meta-analysis on selective versus comprehensive neck dissection in oral squamous cell carcinoma patients with clinically node-positive neck. Oral Oncol 51:1076–1081CrossRefPubMed
18.
Cariati P, Cabello Serrano A, Fernandez Solis J et al (2018) Distribution of cervical metastasis in tongue cancer: are occult metastases predictable? A retrospective study of 117 oral tongue carcinomas. J Craniomaxillofac Surg 46(1):155–161CrossRefPubMed
19.
Inoue H, Nibu K, Saito M et al (2006) Quality of life after neck dissection. Arch Otolaryngol Head Neck Surg 132(6):662–666CrossRefPubMed
20.
Ridge JA, Lydiatt WM, Patel SG et al (2017) Part II 7. Lip and oral cavity. In: Avin MB (ed) AJCC cancer staging manual, 8th edn. Springer, Switzerland, pp 79–94CrossRef
Metadata
Title
Extent of neck dissection for patients with clinical N1 oral cancer
Authors
Yasumasa Kakei
Hirokazu Komatsu
Tsutomu Minamikawa
Takumi Hasegawa
Masanori Teshima
Hirotaka Shinomiya
Naoki Otsuki
Ken-ichi Nibu
Masaya Akashi
Publication date
01-06-2020
Publisher
Springer Singapore
Published in
International Journal of Clinical Oncology / Issue 6/2020
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-020-01635-8

Other articles of this Issue 6/2020

International Journal of Clinical Oncology 6/2020 Go to the issue

Original Article

Calpain suppresses cell growth and invasion of glioblastoma multiforme by producing the cleavage of filamin A

Original Article

Comparison of involved field radiotherapy and elective nodal irradiation in combination with concurrent chemotherapy for T1bN0M0 esophageal cancer

Invited Review Article

Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems

Original Article

Prognostic significance of β2-adrenergic receptor expression in patients with surgically resected colorectal cancer

Original Article

Down-regulation of miR-200c associates with poor prognosis of oral squamous cell carcinoma

Original Article

Efficacy and feasibility of S-1 plus oxaliplatin (C-SOX) for treating patients with stage III colon cancer (KSCC1303): final analysis of 3-year disease-free survival
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits